Drug intelligence / Profile preview

APX801

Development stage: Preclinical
Lead developer: Pyxis Oncology
Modality: T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

APX801 is a natural killer (NK) cell engager designed to specifically activate NK cells, leading to effective killing of tumor cells. It is an immuno-oncology agent developed for cancer therapy, aiming to harness the innate immune system by engaging and activating NK cells against malignant targets. The drug was originally developed by Apexigen and later acquired by Pyxis Oncology in August 2023. As of the latest updates, APX801 remains at the pre-clinical stage with development previously paused by Apexigen[1][5][7].

Targets

NCR2 (Natural cytotoxicity triggering receptor 2)

Beyond the preview

Go deeper on APX801.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APX801.

Explore the full profile